prescription drug costs

Even the savviest Medicare drug plan shoppers can get a shock when they fill prescriptions: That great deal on medications in fall is no bargain after prices go up as much as 8% by winter.

The pharmacy says it will bypass health care industry "middlemen" and help consumers avoid high drug prices by charging manufacturers' prices plus a flat 15% markup and pharmacist fee.

The move comes just days before a U.S. rule was set to go into effect allowing for bulk importation of drugs from Canada. Trump promised it would lower costs and be a "game changer" for seniors.

Some polls show Trump's support slipping among seniors. His new plan will help diabetic seniors limit insulin costs to $35 per month, starting next year.

Lawmakers Thursday passed a bill to rein in drug costs. President Trump has vowed to veto it. But the plan shares a lot with other bipartisan efforts. Here's how it would work.

Drugmakers hate the idea. But Nancy Pelosi and Donald Trump both say pegging the prices of U.S. medicine to what people elsewhere pay could save U.S. patients a bundle. Here's how an "IPI" might work.

The snakebite antivenin CroFab, on the U.S. market since 2000, now faces competition from a drug called Anavip. But both are expensive. "Perverse incentives" keep prices high, says one legal scholar.

Iron-deficiency anemia is often remedied with drugstore iron pills. But if that doesn't work, doctors sometimes prescribe iron infusions — and the bill for that can vary by thousands of dollars. Why?

A pricing tool embedded in many prescribing and medical records systems lets doctors see how much each patient is likely to pay out of pocket for medicine. But the tools could be better, doctors say.

A new law would let the state make bulk purchases of prescription drugs from Canada. But it still faces hurdles that could keep it from becoming reality.

The Senate Finance Committee will hear Tuesday from executives from the biggest pharmacy benefit managers. Confidential rebates paid to the PBMs are expected to draw scrutiny.

As congressional lawmakers continue to turn up the heat on drugmakers, insurers and middlemen over the price of many medicines, one player says it will limit patients' share of the cost of insulin.